[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cannabis-use-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cannabis-use-disorder":615},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,41,0,25,[9,46,70,118,145,165,185,212,250,272,291,308,330,356,382,405,426,451,467,490,508,526,548,570,595],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100584583",false,"NCT06891235","Study of an Oral Fluid Testing Approach","Oral Fluid Testing to Assess Cannabis Non-Use in Remote Clinical Trials","SOFTA","Inclusion Criteria:\n\n* Age 18 to 30 years\n* Cannabis use on \\>=1x\u002Fweek in the past 30 days\n* Ownership of a portable device that is capable of videoconference and videorecording (i.e., smartphone, tablet computer, or laptop computer)\n* Ability to read and speak English\n* Availability for duration of the study (3-4 weeks).\n* To proceed to oral fluid testing, positive result for urinary TCH-COOH\n\nExclusion Criteria:\n\n• Inability\u002Funwillingness to provide contact information","ALL","18 Years","30 Years",{"count":21,"type":22},200,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to identify and evaluate oral fluid testing as a biologic measure of cannabis use days that can be assessed remotely. The researchers will conduct this fully virtual study among a community sample of 200 individuals aged 18-30 years who have used cannabis at least 1 time per week on average in the past 30 days. Participants will complete oral fluid (saliva) tests, urine tests, and Timeline Follow-back interviews (self-report) that indicate their recent cannabis use (delta-9-THC). Participants will present for 3 virtual study visits across \\~3-4 weeks and be asked to complete activities in between: Study Visit 1 (Day 0; informed consent, baseline survey, TLFB interview), Study Visit 2 (\\~Day 7; TLFB interview, urine testing), 6 days of at-home videorecorded oral fluid testing, Study Visit 3 (\\~Day 21; TLFB interview, urine test, oral fluid test, survey, interview).",[26,27,28],"Cannabis Use","Cannabis Intoxication","Cannabis Use Disorder",[30,31,32],"cannabis use","young adult","oral fluid testing","RECRUITING","2026-06-27",{"date":36,"type":37},"2026-07-01","ACTUAL",{"date":39,"type":37},"2025-10-27",{"date":41,"type":22},"2027-05",{"name":43,"class":44},"Boston Children's Hospital","OTHER",1,{"id":47,"slug":4,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":45},"100474101","NCT05453513","The Neural Underpinnings of Depression and Cannabis Use in Young People Living With HIV","Inclusion Criteria:\n\n* HIV seropositivity confirmed with lab report, medical records, or HIV testing.\n* Between the ages of 18-39 years\n* Fluency in English or Spanish\n* Ability to provide informed consent and perform study procedures, including estimated full-scale intelligence quotient (IQ) \\>75 to ensure that participants are able to understand the study.\n* Cannabis users: To capture a wide range of cannabis use frequency, meeting Diagnostic and Statistical Manual 5 (DSM-5) criteria for Cannabis use Disorder (CUD) will not be required. However, in order to ensure sufficient exposure, cannabis use will be significant (self-reported use on ≥20 of the prior 30 days and positive THC urine toxicology).\n* Depressed: In order to capture a wide range of depression illness severity, we will allow participants with subthreshold depression, defined as a raw severity score of ≥12 on the Montgomery Asberg Depression Rating Scale (MADRS).\n\nExclusion Criteria:\n\n* Perinatally acquired HIV infection, as early neurodevelopmental alterations and HIV legacy effects may exist in this group\n* Pregnancy or lactation\n* Current Substance Use Disorder other than cannabis or nicotine\n* Certified for or self-reported medical cannabis use, or intent to become certified\n* Current cocaine use by self-report or urine toxicology\n* central nervous system (CNS) disease or injury, or neuro-degenerative disease\n* Unique pain syndromes (e.g. multiple sclerosis, rheumatoid arthritis);\n* Severe medical illness such as end-stage renal disease, heart failure, cirrhosis, or cancer\n* MRI contraindication such as claustrophobia, metallic ink tattoos, or pacemaker.\n\nDepressed cannabis non-users:\n\n* At baseline, all participants will be psychotropic-medication-free for ≥1 month prior to study enrollment (or ≥3 months for medications with longer half-lives). Benzodiazepines and sleeping aids taken on an as-needed basis will be allowed, however we will require a 4-day abstinence period before the scan.\n* Exclusionary are participants with a DSM-5 diagnoses of bipolar disorder, psychotic disorders, autism spectrum disorders, and all non-cannabis substance-related disorders will be exclusionary. disorder (PTSD) are not uncommon among depressed individuals and will be\n* Anxiety disorders, obsessive-compulsive disorder (OCD), and post-traumatic stress are allowed as long as depressive symptoms are primary.\n\natypical of depression. • Suicidal ideations (SI) without a specific plan (defined as passive SI) are common in depression and will be allowed. However, if SI constitutes an imminent risk to self or others (defined as active SI), the participant will be withdrawn from the study and emergency procedures will be initiated immediately, including ER admission.\n\nDepressed cannabis users:\n\n• Exclusion criteria will be the same as depressed cannabis non-users except for cannabis use.\n\nNon-depressed cannabis users:\n\n• Will have no major psychiatric conditions other than cannabis use\u002Fdisorder.\n\nNon-depressed cannabis non-users:\n\n• Exclusion criteria will be the same as for non-depressed cannabis users; in addition participants will not report cannabis use in the prior 90 days and have a urine toxicology test negative for cannabis.","59 Years",{"count":53,"type":22},280,"INTERVENTIONAL",[56],"NA","To elucidate mechanisms of substance use disorders (SUD) and comorbid mental illnesses in people living with HIV (PLWH), the study team seeks to investigate reward and pain circuitry in cannabis use and depression comorbidity, two highly prevalent conditions in PLWH. The study team proposes a tightly integrative study to test the overall hypothesis that cannabis use and depression in young PLWH have an additive effect, inducing both reward deficits and pain hypersensitivity, and that this pattern will predict worse outcomes at 1 year follow-up.",[59,28,60],"Depression","HIV","2026-06-24",{"date":63,"type":37},"2026-06-29",{"date":65,"type":37},"2022-04-01",{"date":67,"type":22},"2027-07-30",{"name":69,"class":44},"University of Miami",{"id":71,"slug":4,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":54,"phases":81,"briefSummary":82,"conditions":83,"keywords":107,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":45},"100619125","NCT07340554","Neuroimaging of Adolescent Cannabis Use Treatment","Neuroimaging of Instrumental Learning Networks in Adolescent Cannabis Use Treatment","ACT","Inclusion Criteria:\n\n* 14-17 year old youth\n* Guardian 18 years or older\n* Youth is MRI-eligible: No metal implants, prosthetics, orthodontic devices, transdermal medication patches, piercings and\u002For hair or eyelash extensions that cannot easily be removed, metallic ink tattoos on the neck or face, or claustrophobia, and are not pregnant\n* Youth must endorse having used cannabis at least once per week over the past month OR youth must have been diagnosed with cannabis use disorder within the past three months\n\nExclusion Criteria:\n\n* Youth has a history of Fetal Alcohol Spectrum Disorder, intellectual disorders, pervasive development disorder or autism spectrum disorder, psychotic disorders, history of neurological problems (epilepsy, traumatic brain injury, brain tumor, cerebrovascular disease) by parent\u002Fguardian report\n* Youth or caretaker who is monolingual non-English speaker\n* Youth who is currently experiencing active psychosis symptoms or suicidal\u002Fhomicidal ideation or who has been hospitalized within the past 6 months for psychosis or suicidality\u002Fhomicidality\n* Youth who is currently undergoing contingency management treatment for cannabis use disorder","14 Years","17 Years",{"count":80,"type":22},80,[56],"This study is testing whether brain activity related to learning can help predict how well teens respond to a treatment program designed to reduce cannabis use. Teens ages 14-17 will complete a brain scan and then take part in 10 weekly virtual sessions where they report cannabis use and complete drug tests at home. Participants can earn prizes for staying cannabis-free.",[26,84,28,85,27,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106],"Cannabis Dependence","Cannabis Abuse","Cannabis Smoking","Cannabis Withdrawal","Cannabis-Related Disorder","Cannabis Abuse, in Remission","Cannabis Abuse, Episodic Use","Marijuana","Marijuana Abuse","Marijuana Use","Marijuana Smoking","Marijuana Dependence","Marijuana User","Marijuana-Related Disorder","Marijuana Use Disorder","Addiction","Addiction, Substance","Substance Use","Substance Use Disorders","Substance Dependence","Substance Abuse","Substance Related Problem","Substance Abuse Drug Chronic",[108,91,99],"Cannabis","2026-06-18",{"date":111,"type":37},"2026-06-22",{"date":113,"type":37},"2026-06-15",{"date":115,"type":22},"2030-05-01",{"name":117,"class":44},"Indiana University",{"id":119,"slug":4,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":125,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":54,"phases":128,"briefSummary":130,"conditions":131,"keywords":132,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":45},"100524310","NCT06107062","Longitudinal Outpatient Treatment for Cannabis Use Disorder","Hemp-derived Cannabidiol for the Treatment of Cannabis Use Disorder: A Double-blind Placebo-controlled Randomized Trial","LOTUS","Inclusion Criteria:\n\n* Regular use (at least 4 times per week) of cannabis concentrates for at least the last year.\n* Meets DSM5 criteria for at least moderate CUD.\n* Currently seeking to cut down or stop cannabis use.\n\nExclusion Criteria:\n\n* Use of any substance of abuse besides alcohol, nicotine, or cannabis (e.g., cocaine, non-prescription use of opiates, methamphetamine, MDMA, benzodiazepines, or barbiturates) in the past 90 days, as indicated by self-report and urine toxicology screening (Syva Rapid Test) at baseline.\n* Use of CBD-dominant products in the past 90 days, as evidenced by self-report of use of a CBD\\>THC product or CBD blood levels at baseline of \\>= 5 ng\u002FmL\n* Alcohol use on 3 or more days per week, and\u002For \\> 3 drinks per drinking day in the past 90 days. Participants must also have a breath alcohol level of 0 at the beginning of each study visit.\n* Daily nicotine use.\n* Meets DSM-5 diagnostic criteria for a psychotic disorder (e.g., schizophrenia, schizophreniform disorder, schizoaffective disorder), bipolar disorder, or major depression with suicidal ideation, or has a history of treatment for these disorders. Psychiatric disorders will be assessed with the Mini-International Neuropsychiatric Interview (MINI).\n* Current cardiovascular or respiratory disease (e.g., coronary artery disease, severe asthma, chronic obstructive pulmonary disease, etc.)\n* Current use of psychotropics (e.g., antidepressants, anxiogenics), which may dampen effects of CBD.\n* Current use of anti-epileptic medications (e.g., clobazam, sodium valproate) or medications known to have major interactions with Epidiolex (buprenorphine, leflunomide, levomethadyl acetate, lomitapide, mipomersen, pexidartinib, propoxyphene, sodium oxybate, and\u002For teriflunomide).\n* Current or past hepatocellular disease, as indicated by alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 2 times the upper limit of the normal range at screening or a history of liver disease irrespective of AST and ALT at the time of screening.\n* For participants assigned female at birth, pregnancy or trying to become pregnant as indicated by a urine pregnancy test administered at the beginning of each study visit.\n* History of seizures\n* Current use of potent CYP2C19 or CYP3A4 inducers (e.g., Rifampin, apalutamide, carbamazepine, enzalutamide, ivosidenib9, lumacaftor, ivacaftor, phenytoin, St. John's wort, Fosphenytoin, Mitotane, Phenobarbital, Primidone), or strong CYP3A inhibitors (e.g., clarithromycin, HIV protease inhibitors, and most antifungals), 2C19 inhibitors (e.g., fluoxetine, Lansoprazole, Tricyclic antidepressants (TCAs))\n* Allergy to study medications (hemp seed oil, hemp extract, gelatin, glycerin)","21 Years",{"count":127,"type":22},165,[129],"PHASE2","This study is a placebo-controlled randomized trial comparing the effects of hemp-derived cannabidiol (CBD) with and without Delta-9-tetrahydrocannabinol (THC), relative to placebo, on reducing cannabis use and cannabis use disorder (CUD) symptoms in adult treatment seeking cannabis concentrate users with CUD. Participants enroll in the study for 8 weeks (with telehealth follow-ups at 12 and 16 weeks) and are randomized to either full spectrum CBD, broad spectrum CBD, or placebo. Participants are also engaged in five weeks of psychotherapy treatment for CUD. Blood is collected to quantify investigational drug exposure and cannabis use. Participants also complete self-report measures of medical history, sleep quality, subjective cognitive function, physical activity, psychological functioning, substance use, and acute drug effects.",[28],[28,133,134,135],"CUD","Cannabidiol","CBD","2026-06-10",{"date":138,"type":37},"2026-06-12",{"date":140,"type":37},"2024-07-26",{"date":142,"type":22},"2029-03-31",{"name":144,"class":44},"University of Colorado, Boulder",{"id":146,"slug":4,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":17,"minAge":150,"maxAge":125,"enrollmentInfo":151,"targetDuration":4,"studyType":54,"phases":153,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":163,"locationsCount":45},"100643636","NCT07634835","Transcranial Magnetic Stimulation for Adolescents and Young Adults With Cannabis Use Disorder","Inclusion Criteria:\n\n* 15-21 years old\n* For minors, parent\u002Flegal guardian able to provide consent and child able to provide assent; for adults, ability to self-consent per MacArthur Competence Assessment Tool for Clinical Research\n* Ability to comply with study procedures\n* Treatment-seeking youth diagnosed with CUD as per the Mini-International Neuropsychiatric Interview (MINI-KID (Sheehan et al., 2010) for 15-17 years old and MINI (Sheehan et al., 1998) for 18-21 years old)\n* Cannabis use 3+ days per week (or 12+ days in the past month) as verified by Timeline Followback (TLFB) (Sobell \\& Sobell, 1996)\n* Fluent in spoken English\n\nExclusion Criteria:\n\n* Medical conditions contraindicated or associated with altered TMS risk profile, including history of intracranial pathology, intracranial lesions, epilepsy or seizure disorders, or individuals with a family history of epilepsy or seizure in a first degree relative, traumatic brain injury, brain tumor, stroke, neurocardiogenic syncope, mania\u002Fbipolar disorder, implanted medical devices or metallic objects in the head, current pregnancy or not using effective contraception if capable of becoming pregnant, or any other serious medical condition or contraindication as judged by the study physician; moderate to severe heart disease, pediatric populations with risk factors for neurocardiogenic syncope (history of syncope\u002Fpresyncope related to noxious stimuli, anxiety, micturation, or posture)\n* Inability to undergo MRI.\n* Diagnosis of psychosis, cognitive disability or active suicidality. The MINI (Sheehan et al., 1998, 2010) will be used to assess current psychiatric comorbidities and the Ask Suicide-Screening Questions (ASQ) will be used to assess suicidality (Horowitz et al., 2012).\n* Primary current alcohol or substance use disorder, except for caffeine or nicotine.\n* Taking a medication with high seizurogenic potential (e.g., clomipramine, tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, anti-psychotics, lithium, bupropion -e.g. Wellbutrin). Participants taking psychotropic medications will be included if dose is stable for ≥4 weeks with no anticipated changes during the study period. All concurrent treatments will be monitored during the study period.\n\n  * If an individual is currently taking antibiotics that affect the central nervous system such as Fluoroquinolones (Ciprofloxacin, Levofloxacin, Moxifloxacin) or Imipenem, medications that have the potential of lowering seizure threshold, participation in the study will be delayed until 5 days after the last antibiotic dose.\n  * If an individual is taking antihistamines (i.e. Benadryl\u002Fdiphenhydramine), they will be asked to refrain from using the antihistamine for at least 24 hours before the TMS session. If the participant is not able to do so, they will be excluded from the study.","15 Years",{"count":152,"type":22},50,[56],"This pilot study will investigate the potential of repetitive transcranial magnetic stimulation (rTMS) to strengthen a neural circuit critical for maintaining abstinence in adolescents and youth with cannabis use disorder (CUD).",[26,28],"NOT_YET_RECRUITING","2026-06-02",{"date":159,"type":37},"2026-06-09",{"date":161,"type":22},"2027-03-01",{"date":142,"type":22},{"name":164,"class":44},"University of Minnesota",{"id":166,"slug":4,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":54,"phases":172,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":45},"100583633","NCT06878859","Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use","AMP-C: A Digital Therapeutic for Reward Dysfunction in Co-Occurring Depression and Cannabis Use","Inclusion Criteria:\n\n* Aged ≥ 18 years\n* Resides in the United States\n* Able to read and understand English and willing to provide informed consent\u002Fcomply with the study protocol\n* Moderate depressive symptom severity, as indicated by the Patient Health Questionnaire-9 (PHQ-9)\n* Problematic cannabis use, as indicated by the Cannabis Use Disorder Identification Test - Revised (CUDIT-R)\n* Current elevated anhedonia, as indicated by the PHQ-9\n* Interest in receiving treatment for their cannabis use and depression\n* Meet criteria for current MDD and CUD per the DSM-5\n\nExclusion Criteria:\n\n* History of a psychotic disorder or bipolar disorder type I\u002FII\n* Active suicidal ideation or intent based on the Columbia-Suicide Severity Rating Scale\n* Current psychotherapy engagement\n* Changes in psychotropic medication within six weeks of the start of study",{"count":80,"type":22},[56],"The purpose of this study is to examine the feasibility, acceptability, and preliminary efficacy of a digital intervention for co-occurring cannabis use and depression. Participants will be randomized to complete Amplification of Positivity - Cannabis Use (AMP-C) or symptom tracking. The main outcomes will include changes in depressive symptoms and cannabis use, as well as usability ratings.",[175,28,176],"Depression - Major Depressive Disorder","Mental Disorder","2026-06-01",{"date":157,"type":37},{"date":180,"type":37},"2026-02-23",{"date":182,"type":22},"2029-06-29",{"name":184,"class":44},"Massachusetts General Hospital",{"id":186,"slug":4,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":191,"sex":17,"minAge":192,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":54,"phases":196,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":210,"locationsCount":45},"100473460","NCT05445180","Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use","Investigating the Neural Correlates of Cognitive Function Associated With Cannabis Abstinence in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use","Inclusion Criteria:\n\n* Able to provide informed consent in English or French\n* Heavy cannabis use (defined as weekly cannabis use for at six months) and\u002For DSM-5 diagnosis of CUD\n* Have a Full-Scale IQ ≥ 75\n* Meet DSM-5 criteria for a psychotic disorder (psychosis patient arm only)\n* Be an outpatient receiving a stable dose of medication(s) for at least two months (psychosis patient arm only)\n* Clinically stable (as measured by the PANSS-6, total score \\\u003C30) (psychosis patient arm only)\n\nExclusion Criteria:\n\n* current SUD (other than CUD)\n* MRI contraindications\n* Positive urine screen for psychoactive substances other than cannabis, nicotine, or caffeine\n* Current suicidal or homicidal ideation\n* Head injury requiring hospitalization or loss of consciousness \\> 5 minutes\n* Current medical diseases that requires hospitalization or regular monitoring\n* Being pregnant\n* DSM-5 Axis 1 diagnosis (other than CUD) (non-psychiatric controls only)\n* Taking psychotropic medication",true,"16 Years","80 Years",{"count":195,"type":22},134,[56],"Cognitive impairment is well established in people with psychosis and is associated with cannabis use. The current study will investigate the neurobiological basis of cognitive change associated with 28-days of cannabis abstinence in people with psychosis and non-psychiatric controls with cannabis use. Participants will be randomized to a cannabis abstinent group or a non-abstinent control group and will undergo magnetic resonance imaging at baseline and following 28-days of abstinence. This study will help characterize the neuropathophysiological processes underlying cognitive dysfunction associated with cannabis use and its recovery which may guide the development of novel interventions for problematic cannabis use.",[199,28,84,26,200,201,202,203],"Psychotic Disorders","Schizophrenia; Psychosis","Cognitive Dysfunction","Memory Impairment","Neuroimaging","2026-05-19",{"date":206,"type":37},"2026-05-22",{"date":208,"type":37},"2022-04-21",{"date":41,"type":22},{"name":211,"class":44},"Douglas Mental Health University Institute",{"id":213,"slug":4,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":54,"phases":222,"briefSummary":223,"conditions":224,"keywords":227,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":45},"100633203","NCT07523633","Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder","A Randomized, Double-Blind, Placebo-Controlled Trial of Semaglutide for Reducing Cannabis Use in Adults With Cannabis Use Disorder","HASHTAG","Inclusion Criteria:\n\n1. Informed oral and written consent.\n2. Meets the criteria for cannabis use disorder (CUD) according to DSM-5 or ICD-10.\n3. Currently seeking to cut down or stop cannabis use.\n4. Positive urine test for cannabinoids.\n5. Body mass index (BMI) ≥ 23 kg\u002Fm².\n6. Age 18-70 years.\n7. Recent frequent cannabis use, defined as use on ≥16 days out of the past 28 days.\n8. Cannabis use (smoked, vaped, edibles) equivalent to THC doses of ≥14 grams in the past 28 days before baseline.\n9. Ability to comply with study procedures and follow-up.\n\nExclusion Criteria:\n\n1. Currently meeting non-cannabis\u002Ftobacco substance use disorder (ICD-10 or DSM-5).\n2. Current or past diagnosis of severe psychiatric illness, defined as schizophrenia, bipolar disorder, or other psychoses, within the past five years.\n3. Suicide attempt or suicidal behavior within the past five years.\n4. Severe neurological disorders, including previous severe traumatic brain injury, stroke, or intracranial hemorrhage.\n5. Type 1 diabetes and type 2 diabetes.\n6. Pregnant or potentially pregnant women: Women of childbearing potential (WOCBP) who are pregnant, breastfeeding, planning to become pregnant within the next eight months (including 20 weeks of treatment plus two months after discontinuation of semaglutide), or not using effective contraception throughout the study period. Effective methods include combined hormonal contraception (oral, intravaginal, transdermal), progestogen-only hormonal contraception (oral, implant, injection), intrauterine device\u002Fsystem (IUD\u002FIUS), bilateral tubal occlusion, partner with vasectomy, or sexual abstinence. WOCBP with a measured serum human chorionic gonadotropin (hCG) level \\>3 U\u002FL at inclusion will also be excluded.\n7. Impaired liver function (liver transaminases \\>3 times the upper reference limit)\n8. Impaired renal function (eGFR \\\u003C50 ml\u002Fmin and\u002For plasma creatinine \\>150 µmol\u002FL).\n9. Impaired pancreatic function (past or current acute or chronic pancreatitis and\u002For amylase \\>2 times the upper limit).\n10. History of medullary thyroid carcinoma (MTC) and\u002For family history of MTC and\u002For Multiple Endocrine Neoplasia type 2 (MEN 2).\n11. Heart disease is defined as decompensated heart failure (NYHA class III or IV), unstable angina pectoris, and\u002For myocardial infarction within the past 12 months.\n12. Uncontrolled hypertension (systolic blood pressure \\>180 mmHg, diastolic blood pressure \\>110 mmHg).\n13. Receipt of experimental medication within the past 30 days.\n14. Use of weight-loss medication within the past 3 months.\n15. Hypersensitivity to the active substance or any of the excipients.\n16. For patients undergoing brain scanning only:\n\n    Contraindications to MRI scanning (magnetic implants, pacemaker, claustrophobia, etc.).\n17. Inability to speak and\u002For understand Danish.\n18. Other conditions: Any other condition that, in the investigator's opinion, may interfere with participation in the trial.","70 Years",{"count":221,"type":22},100,[129],"The HASHTAG Study is investigating whether the medicine semaglutide can help adults with cannabis use disorder (CUD) reduce their cannabis use. Participants will be randomly assigned to receive either semaglutide or a placebo. The first 50 participants will have functional brain scans (fMRI) to investigate how the brain responds to cannabis-related cues. The main outcome after 20 weeks is whether semaglutide reduces cannabis use compared to placebo. Changes in brain activity in response to cannabis cues will be explored as a secondary outcome.",[28,225,85,84,226],"Cannabis Use Disorders","Cannabis Addiction",[228,229,230,231,232,233,234,235,236,203,237,238,239,240],"GLP-1","Glucagon-like peptide 1","semaglutide","fMRI","cannabis","GLP-1 receptor agonist","Randomized Controlled Trial","Double-Blind Method","Placebo-Controlled","Brain activity","Cue reactivity","Craving","Drug therapy","2026-05-12",{"date":243,"type":37},"2026-05-14",{"date":245,"type":37},"2026-04-30",{"date":247,"type":22},"2028-04-30",{"name":249,"class":44},"Anders Fink-Jensen, MD, DMSci",{"id":251,"slug":4,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":17,"minAge":125,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":54,"phases":259,"briefSummary":260,"conditions":261,"keywords":262,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":45},"100610299","NCT07225777","Sex Differences in Neurobehavioral Response to THC","Sex Differences in Neurobehavioral Response to Acute THC in Adults With Cannabis Use Disorder","Inclusion Criteria:\n\n* Age 21-45\n* DSM-5 criteria for CUD\n* Cannabis use ≥4 days\u002Fweek\n* THC-positive urine\n* BMI 18-30\n* Regular menstrual cycle (females)\n* Willingness to use non-hormonal birth control (females)\n\nExclusion Criteria:\n\n* Lifetime psychotic or bipolar disorder\n* Recent drug use other than cannabis\n* Current psychotropic medication\n* Treatment-seeking for SUD\n* Current psychiatric disorder (except mild alcohol, nicotine, or caffeine use disorder)\n* Pregnancy\u002Fnursing\n* MRI contraindications","45 Years",{"count":258,"type":22},40,[129],"This study investigates sex differences in reward processing following acute THC administration in adults with cannabis use disorder (CUD). Using multimodal neuroimaging (MRS and fMRI), the study will assess glutamate levels in the nucleus accumbens and striatal BOLD response to monetary reward anticipation. Participants will complete two counterbalanced dosing sessions (oral THC 40 mg vs. placebo).",[28],[101],"2026-05-04",{"date":265,"type":37},"2026-05-06",{"date":267,"type":37},"2026-04-27",{"date":269,"type":22},"2027-12-31",{"name":271,"class":44},"Medical University of South Carolina",{"id":273,"slug":4,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":278,"enrollmentInfo":279,"targetDuration":4,"studyType":54,"phases":280,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":45},"100559842","NCT06569394","A Study of Cannabidiol in Young Adult Cannabis Users","A Randomized, Placebo Controlled Study of Cannabidiol in Young Adult Cannabis Users","Inclusion Criteria:\n\n1. Ages 18-25\n2. Must have used cannabis flower or concentrates at least five days per week for the past year.\n3. Currently not seeking to cut down or stop cannabis use\n4. At least two symptoms of a DSM-5 cannabis use disorder\n\nExclusion Criteria:\n\n1. Use of any illicit substance besides alcohol, nicotine, or cannabis (e.g., cocaine, opiates, methamphetamine, MDMA, benzodiazepines, or barbiturates) in the past 60 days, as indicated by self-report and urine toxicology screening at the beginning of each study visit.\n2. Alcohol use on 3 or more days per week, and\u002For \\>3 drinks per drinking day in the past 60 days. Participants must also have a breath alcohol level of 0 at the beginning of each study visit.\n3. Daily nicotine use.\n4. Meets DSM-5 diagnostic criteria for a psychotic disorder (e.g., schizophrenia, schizophreniform disorder, schizoaffective disorder), bipolar disorder, major depression with suicidal ideation, or a history of treatment for these disorders.\n5. Current cardiovascular or respiratory disease (e.g., coronary artery disease, severe asthma, chronic obstructive pulmonary disease)\n6. Current use of any psychotropic (e.g., antidepressants, anxiogenics) or hepatotoxic medication.\n7. Current use of anti-epileptic medications (e.g., clobazam, sodium valproate) or medications known to have major interactions with Epidiolex (buprenorphine, leflunomide, levomethadyl acetate, lomitapide, mipomersen, pexidartinib, propoxyphene, sodium oxybate, and\u002For teriflunomide) or a history of seizures.\n8. Current use of strong or moderate CYP3A4 inhibitors or inducers (commonly used examples not captured by other exclusion criteria include protease inhibitors, macrolide antibiotics \\[e.g., erythromycin\\], azole antifungals \\[e.g., ketoconazole\\], verapamil, and grapefruit juice).\n9. Current use of strong or moderate CYP2C19 inhibitors or inducers (commonly used examples not captured by other exclusion criteria include proton pump inhibitors, prednisone, and norethisterone).\n10. Current or past hepatocellular disease, as indicated by medical history or alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin greater than two times the upper limit of the normal range at screening.\n11. For female participants, pregnancy or trying to become pregnant. A positive pregnancy test at the beginning of any study visit will result in exclusion from ongoing study participation.\n12. For female participants, currently lactating.\n13. For female patients of childbearing potential, not willing to use at least one approved method of birth control while taking the study medication, unless she is surgically sterile, partner is surgically sterile, or she is postmenopausal (one year).\n14. Current suicidality risk as indicated during the conduct of the C-SSRS with concurrence after a study physician's or PI evaluation if the response to C-SSRS questions 1 or 2 is \"yes\"","25 Years",{"count":21,"type":22},[129],"The investigators will study the harm-reducing effect of hemp-derived CBD in non-treatment-seeking emerging adults who use cannabis regularly. The study will use a novel naturalistic cannabis administration approach, which examines ecologically valid cannabis use utilizing a mobile lab setting to assess the effects of the cannabis products the participants regularly use. The investigators will recruit a sample of emerging adults, half of whom primarily use flower products and half of whom primarily use concentrate products. Individuals will be randomly assigned to hemp-derived CBD or placebo.",[28],{"date":284,"type":37},"2026-05-01",{"date":286,"type":37},"2024-12-09",{"date":288,"type":22},"2028-06-30",{"name":290,"class":44},"University of Colorado, Denver",{"id":292,"slug":4,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":17,"minAge":278,"maxAge":297,"enrollmentInfo":298,"targetDuration":4,"studyType":54,"phases":300,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":303,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":307,"locationsCount":45},"100560331","NCT06575751","Cannabidiol and Cannabis Concentrate Users","Cannabidiol and Cannabis Concentrate Users: A Randomized, Placebo Controlled Study","Inclusion Criteria:\n\n1. Age 25-60.\n2. Regular use (at least 4 times per week) of cannabis concentrates for the last year.\n3. Not currently seeking to cut down or stop cannabis use.\n4. At least one episode of 3 consecutive days of cannabis abstinence with no experience of severe withdrawal symptoms (i.e., \\>=4 DSM-5 Cannabis Withdrawal symptoms rated as \"severe\"), in the last 90 days.\n5. At least two symptoms of a DSM-5 cannabis use disorder.\n\nExclusion Criteria:\n\n1. Use of any illicit substance besides alcohol, nicotine, or cannabis (e.g., cocaine, opiates, methamphetamine, MDMA, benzodiazepines, or barbiturates) in the past 60 days, as indicated by self-report and urine toxicology screening at the beginning of each study visit.\n2. Use of CBD-containing products other than cannabis concentrates in the past 90 days.\n3. Alcohol use on 3 or more days per week, and\u002For \\> 3 drinks per drinking day in the past 60 days. Participants must also have a breath alcohol level of 0 at the beginning of each study visit.\n4. Daily nicotine use.\n5. Meets DSM-5 diagnostic criteria for a psychotic disorder (e.g., schizophrenia, schizophreniform disorder, schizoaffective disorder), bipolar disorder, or major depression with suicidal ideation, or has a history of treatment for these disorders.\n6. Current cardiovascular or respiratory disease (e.g., coronary artery disease, severe asthma, chronic obstructive pulmonary disease, etc.)\n7. Current use of any psychotropic (e.g., antidepressants, anxiogenics) or hepatotoxic medications.\n8. Currently use of anti-epileptic medications (e.g., clobazam, sodium valproate) or medications known to have major interactions with Epidiolex (buprenorphine, leflunomide, levomethadyl acetate, lomitapide, mipomersen, pexidartinib, propoxyphene, sodium oxybate, and\u002For teriflunomide) or a history of seizures.\n9. Current use of strong or moderate CYP3A4 inhibitors or inducers (commonly used examples not captured by other exclusion criteria include protease inhibitors, macrolide antibiotics \\[e.g., erythromycin\\], azole antifungals \\[e.g., ketoconazole\\], verapamil, and grapefruit juice).\n10. Current use of strong or moderate CYP2C19 inhibitors or inducers (commonly used examples not captured by other exclusion criteria include proton pump inhibitors, prednisone, and norethisterone).\n11. Current or past hepatocellular disease, as indicated by medical history or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 2 times the upper limit of the normal range at screening.\n12. For female participants, pregnancy or trying to become pregnant. A positive pregnancy test at the beginning of any study visit will result in exclusion from ongoing study participation.\n13. For female participants, currently lactating.\n14. For female patients of childbearing potential, not willing to use at least an approved method of birth control while taking the study medication, unless she is surgically sterile, partner is surgically sterile or she is postmenopausal (one year).\n15. Current suicidality risk as indicated during the conduct of the C-SSRS with concurrence after a study physician's or PI evaluation if the response to C-SSRS questions 1 or 2 is \"yes\".","60 Years",{"count":299,"type":22},120,[129],"This study is a randomized, placebo-controlled, dose-ranging trial of plant-derived cannabidiol (CBD) among people who regularly use cannabis concentrates but are not trying to stop or cut down on their use. The main questions it aims to answer are whether CBD, relative to placebo, reduces cannabis concentrate use, the subjective effects of cannabis, or cannabis craving. Participants will take CBD (200 mg or 400 mg per day) or placebo for 4 weeks and will complete three visits during the study medication period, all conducted using a mobile laboratory.",[28],{"date":284,"type":37},{"date":305,"type":37},"2024-12-04",{"date":288,"type":22},{"name":290,"class":44},{"id":309,"slug":4,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":191,"sex":17,"minAge":18,"maxAge":315,"enrollmentInfo":316,"targetDuration":4,"studyType":54,"phases":317,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":45},"100576408","NCT06784908","Stress and Pain in People Living With HIV","Stress-immune Mechanisms for People Living With HIV, CUD and Depression","HIV Stress","Inclusion Criteria:\n\n* good health as verified by screening examination\n* Able to read English and complete study evaluations and provide informed written and verbal consent. Additional criteria PLWH\n* HIV-1 lab test positive\n* undetectable viral load\n* good ART adherence\n\nAdditional criteria by group:\n\nPLWH +CM:\n\n* CB positive urine toxicology\n* meet DSM-5 criteria for CUD and MDD as assessed using SCID-I. HC\n* HIV-1 test negative\n* urine toxicology negative\n* no major medical and psychiatric diagnoses based on DSM-V.\n\nPLWH Only:\n\n* HIV-1 test positive\n* urine toxicology negative\n* no major medical and psychiatric diagnoses based on DSM-V.\n\nCM Only:\n\n* HIV-1 test negative\n* urine toxicology positive\n* meet DSM-5 criteria for CUD and MDD as assessed using SCID-I\n\nExclusion Criteria:\n\n* meet primary, current moderate and severe criteria for other SUD including cocaine, alcohol, opiates, sedatives, nicotine\n* current use or past history of cocaine or opioid use disorder\n* history of any psychotic disorder\n* current diagnoses of bipolar disorder and PTSD\n* psychotic or otherwise severely psychiatrically disabled (i.e., suicidal, homicidal, current mania)\n* significant underlying medical conditions such as cerebral, renal, thyroid or cardiac pathology that would interfere with study participation\n* medications with known central effects on HPA axis and cytokines\u002Fimmune function\n* women who are pregnant, nursing or those using hormonal birth control that affect HPA axis cortisol responses.","68 Years",{"count":299,"type":22},[56],"This is a basic human experimental study utilizing 4 groups of individuals with and without HIV and complex morbidities of cannabis use disorder and major depression who will participate in 2 sessions of the Yale Pain Stress Task (YPST) and follow-up phase to assess drug use and mood symptoms.",[60,59,28,320,321],"Stress","Pain","2026-04-23",{"date":267,"type":37},{"date":325,"type":37},"2025-01-16",{"date":327,"type":22},"2030-01-31",{"name":329,"class":44},"Yale University",{"id":331,"slug":4,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":54,"phases":337,"briefSummary":338,"conditions":339,"keywords":345,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":45},"100593048","NCT07001371","Emotional Brain Training for Addiction Medicine Treatment - A Pilot Study","Inclusion Criteria:\n\n* Age 18 years old or older\n* Patient can speak and read English\n* Patient who receives regular MAT care at SAC Health\n* Patients who have regular and reliable cellular and\u002For reliable internet connection\n* Patients who are willing to spend average of 25 minutes per day and attend weekly group meetings\n* Patients willing to actively participate in group sessions\n* Opioid use disorder, at least in early remission\n* Alcohol use disorder, at least in early remission\n* Methamphetamine use disorder, at least in early remission\n* Cocaine use disorder, at least in early remission\n* Anxiolytic use disorder, at least in early remission\n* Cannabis use disorder\n* Tobacco use disorder\n\nExclusion Criteria:\n\n* Age \\\u003C18 years old\n* Patient does not speak or read English\n* Patients who do not seek regular MAT care at SAC Health\n* Patients with inconsistent or no access to cellular or internet connection\n* Any disorder that is uncontrolled\n* Any substance use disorder not in at least early remission\n* Any patient with complications related to use disorder\n* Patients enrolled in the Coachella Valley Rescue Mission patients a part of SAC Health\n* Anyone who, in the opinion of the investigators, would be unable to participate in an 8-week trial",{"count":336,"type":22},54,[56],"The goal of this clinical trial is to determine whether Emotional Brain Training (EBT), a behavioral modification method, can help manage stress and health problems related to addiction. EBT teaches skills to deactivate harmful circuits (automatic reactions) and activate healing circuits to quickly shift mood from negative to positive. Participants in the EBT group will receive focused, intensive instruction on using these skills to rewire unwanted brain circuits, with the aim of achieving lasting improvements in emotional health and quality of life. The study will assess whether EBT is an effective tool when added to standard of care (SOC), which includes medications for addiction treatment (MAT).\n\nResearchers will compare changes in stress, anxiety, and cravings after 8 weeks of EBT plus SOC versus SOC alone.\n\nParticipants:\n\n* will either continue receiving standard treatments (SOC) at the Addiction Recovery Clinic (ARC) at SAC Health in San Bernardino\n* or receive both EBT and SOC at ARC\n* in the SOC group will continue monthly visits at ARC and weekly counseling\n* in the EBT plus SOC group will continue monthly visits and weekly counseling at ARC, along with weekly EBT group sessions by telephone\n* will complete online assessments at weeks 0, 4, and 8 Upon completion of the study, all participants will resume SOC",[28,340,341,342,343,344],"Stimulant Use Disorder","Opioid Use Disorder","Tobacco Use Disorder","Alcohol Use Disorder","Sedative, Hypnotic, or Anxiolytic Use Disorders",[346,347],"early remission","sustained remission","2026-04-21",{"date":322,"type":37},{"date":351,"type":22},"2026-08",{"date":353,"type":22},"2027-08",{"name":355,"class":44},"Loma Linda University",{"id":357,"slug":4,"hasResults":11,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":11,"sex":17,"minAge":362,"maxAge":363,"enrollmentInfo":364,"targetDuration":4,"studyType":54,"phases":366,"briefSummary":367,"conditions":368,"keywords":369,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":45},"100607163","NCT07184983","RS-tDCS for Cannabis Use Disorder: The C.A.R.E.S. Initiative","Telehealth-Delivered tDCS for Cannabis Addiction Recovery: The C.A.R.E.S. (Cannabis Addiction Recovery Enhancement Stimulation) Initiative","Inclusion Criteria:\n\n1. Aged 22-65 years (inclusive)\n2. Currently meets the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria for CUD, as determined by DSM-V criteria (M.I.N.I)\n3. Positive for cannabis on the 11-COOH-THC single panel urine test\n4. Seeking treatment to reduce or discontinue cannabis use (Marijuana Ladder ranged between 5-8 \\[inclusive\\])\n5. Kessler Psychological Distress Scale (K10) score \\\u003C 35 (minimal to moderate distress)\n6. Wide Range Achievement Test-5(WRAT-5) score ≥ 85\n7. Ability to use mobile devices\n8. Fluent in English or Spanish\n\nExclusion Criteria:\n\n1. Cannabis is used exclusively as prescribed or directed by their provider\n2. Meets DSM-V criteria for substance use disorder within the past six months for any psychoactive substance other than cannabis\n3. Meets DSM-V criteria for alcohol use disorder within the past six months\n4. Primary psychiatric disorder (major depressive disorder, bipolar disorder, or psychotic disorder) as the principal diagnosis, independent of cannabis use disorder; or current diagnosis of bipolar disorder, psychotic disorder, or any other alcohol\u002Fsubstance use disorder as defined by DSM-5-TR and confirmed via the Mini-International Neuropsychiatric Interview (MINI).\n5. Primary neurologic or major medical disorder that would interfere with study participation.\n6. Enrolled in group or individual therapy for substance use disorder that would be concurrent with the study intervention\n7. History of moderate or severe traumatic brain injury\n8. Seizure disorder or recent (\\\u003C5 years) seizure history\n9. Presence of metal or active implants in the head\u002Fneck\n10. Any skin disorder or skin sensitive area near stimulation locations\n11. Pregnant or planning pregnancy during the study period or breastfeeding","22 Years","65 Years",{"count":365,"type":22},46,[56],"The purpose of this sham-controlled pilot randomized controlled trial (RCT) is to evaluate the feasibility, safety, and preliminary efficacy of a one-month intervention consisting of 20 home-based active or sham RS-tDCS sessions paired with audio track guided mindfulness meditation practice in otherwise healthy adults seeking to reduce cannabis use in the context of cannabis use disorder (CUD).",[28],[108,133,370,371,372,373],"tDCS","Transcranial Direct Current Stimulation","Neuromodulation","Brain Stimulation","2026-04-16",{"date":348,"type":37},{"date":377,"type":37},"2025-11-12",{"date":379,"type":22},"2026-10-01",{"name":381,"class":44},"NYU Langone Health",{"id":383,"slug":4,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":387,"eligibilityCriteria":388,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":278,"enrollmentInfo":389,"targetDuration":4,"studyType":54,"phases":391,"briefSummary":392,"conditions":393,"keywords":394,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":45},"100546473","NCT06395389","A Brief Intervention for Cannabis Use","Development of a Novel Cannabis Brief Intervention for Frequently-Using Emerging Adults: Pilot Randomized Trial","Bloom","Inclusion Criteria:\n\n1. Ages 18-25\n2. Self-Report report cannabis use on at least 20 days of the past 30 days\n3. Submit a positive urine cannabinoid test\n\nExclusion Criteria:\n\n1. Currently engaged in substance use treatment for any type of substance use or currently treatment seeking\n2. History of substance use treatment for any type of substance\n3. Severe alcohol use disorder or indication of any substance use disorder requiring a higher level of care (AUDIT score ≥14 or DUDIT score ≥2 for women, ≥6 for men)\n4. Significant or acutely unstable medical or psychiatric problems (i.e., psychosis, mania) that would contraindicate research procedures, interfere with safety, compromise data integrity, or preclude consistent study participation (Screening psychosis score =7)\n5. Significant risk of suicide or homicide\n6. Currently pregnant or breastfeeding",{"count":390,"type":22},62,[56],"The purpose of this study is to compare two brief interventions targeting potentially problematic cannabis use in emerging adults (ages 18-25). Brief interventions are two 40-50 minute sessions separated by 1 week. Eligible emerging adults will complete a detailed cannabis assessment (biological and self-report), followed by one of the two brief interventions, and four follow-up assessments: one immediately after the second session and at 1-, 3-, and 6-months post-intervention. Assignment to the brief intervention is random. Salivary samples will be collected at baseline, post-intervention, and all follow-ups, for a total of 5 samples, to be tested for tetrahydrocannabinol (THC) and cannabidiol (CBD).",[28],[395,396],"Early intervention","Emerging adults","2026-04-06",{"date":399,"type":37},"2026-04-09",{"date":401,"type":37},"2024-10-18",{"date":403,"type":22},"2029-05",{"name":271,"class":44},{"id":406,"slug":4,"hasResults":11,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":410,"eligibilityCriteria":411,"healthyVolunteers":191,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":54,"phases":413,"briefSummary":415,"conditions":416,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":45},"100583963","NCT06883162","Cannabis-Tobacco Co-Use Treatment Study","Randomized Controlled Trial of Varenicline to Treat Tobacco and Cannabis Co-Use (RECLAIM)","RECLAIM","Inclusion criteria:\n\n1. Ages 18 and over (no upper age limit)\n2. Must smoke at least 5 tobacco cigarettes per day on at least 20 out of the past 30 days for the past 3 months\n3. Must express interest in quitting tobacco\n4. Must express interest in cannabis reduction and\u002For cessation\n5. Must submit a positive instant-read test for cotinine and cannabis prior to enrollment\n6. Must self-report cannabis use (THC-dominant products) on at 3 days per week out of the past 30 days\n7. Must be willing to take varenicline or placebo for 12 weeks\n8. Must reside in South Carolina\n\nExclusion criteria:\n\n1. Any significant or acutely unstable medical, psychiatric, or substance use problem (including clinically significant disorders) that would contraindicate research, interfere with safety, compromise data integrity, or preclude consistent study participation\n2. Pregnant or trying to become pregnant\n3. Use of medications with smoking cessation efficacy\n4. Regular use of e-cigarettes or other tobacco products (\\\u003C10 days in the past month)",{"count":21,"type":22},[414],"PHASE3","The purpose of the RECLAIM study is to evaluate the effectiveness of varenicline (sometimes known as Chantix) compared to placebo (an inactive substance) for the treatment of cigarettes and cannabis (marijuana). Varenicline is not FDA approved for the combination treatment of cigarette abstinence and cannabis reduction or abstinence. All participants will also receive counseling and access to online treatment modules during a quit attempt for cigarettes and a reduction attempt for cannabis. This study is being conducted by the Medical University of South Carolina. All procedures are conducted remotely and there is no in-person visits are needed.\n\nTo qualify, participants must be 18 or older, live in South Carolina, use cigarettes and cannabis, and are interested in quitting cigarettes and reducing cannabis.",[342,417,26,28,93],"Tobacco Use Cessation","2026-04-02",{"date":420,"type":37},"2026-04-03",{"date":422,"type":37},"2025-05-06",{"date":424,"type":22},"2029-01-01",{"name":271,"class":44},{"id":427,"slug":4,"hasResults":11,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":11,"sex":17,"minAge":192,"maxAge":19,"enrollmentInfo":432,"targetDuration":4,"studyType":54,"phases":433,"briefSummary":434,"conditions":435,"keywords":437,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":450},"100597315","NCT07056894","Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis","Evaluating a Brief Virtual Cognitive Remediation Therapy Intervention for Those With Early Phase Psychosis and Substance Misuse in NS\u002FNL: Addressing Challenges in Underserviced Areas","Inclusion Criteria:\n\n* This study will enroll individuals 16-30 years of age from the Early Intervention Services for Psychosis programs in Nova Scotia and the Psychosis Intervention Early Recovery program in Newfoundland\n* Diagnosed with a primary psychotic disorder (e.g. schizophrenia, schizoaffective disorder, and unspecified schizophrenia spectrum disorder)\n* Less than 5 years of psychotic illness\n* Has problematic alcohol and\u002For cannabis use (score of 8 or higher on the World Health Organization Alcohol Use Disorders Identification Test (WHO-AUDIT) or Cannabis Use Disorder Identification Test-Revised (CUDIT-R)).\n\nExclusion Criteria:\n\n* Current stimulant use disorder",{"count":152,"type":22},[56],"Psychotic disorders impact 4.6 people per 1000 globally, with approximately 1.5 million Canadians affected. The age of onset for psychotic disorders often begin during the critical years of youth and early adulthood, resulting in significant challenges for individuals and their families, including difficulties with thinking, relationships, and overall well-being. They also carry significant economic costs, both for health care and lost productivity. Early intervention services have been shown to improve outcomes when provided during the first few years of illness known as early phase psychosis (EPP). However, substance use, especially alcohol and cannabis, can interfere with the effectiveness of these services. Many young people with psychosis misuse these substances, which can harm brain development, worsen symptoms, reduce medication use, and lower quality of life. Despite understanding the risks, there are few effective ways to reduce substance misuse in patients with EPP.\n\nOne promising approach to reducing substance misuse in this population is cognitive remediation therapy, which helps improve thinking skills and everyday functioning. Studies have found that some cognitive remediation therapies can help reduce alcohol use in chronic schizophrenia, but there is limited research targeting the EPP population. Our research team at the Nova Scotia Early Psychosis Program recently completed a pilot study that indicated a therapy called Cognitive Enhancement Therapy (CET) helped participants reduce their problematic alcohol and cannabis use. However, challenges with recruitment and lower attendance rates noted towards the end of the 6-month therapy course suggests that patients with EPP would benefit more from a therapy with a shorter timeframe. Alternatively, Action-Based Cognitive Remediation (ABCR) targets the same cognitive domains believed to help reduce substance use as CET, but has a shorter, more concise schedule. ABCR cover 16 sessions delivered bi-weekly for 2 months, compared to 45 sessions over 6 months of CET. ABCR has been tested in the EPP population and has shown positive results when delivered in person, hybrid and remotely. Although this therapy is demonstrating benefits for patients including improvement in daily functioning and social cognition, its effects on substance misuse have not been researched. This study aims to investigate whether treatment with ABCR helps patients with EPP reduce their alcohol and\u002For cannabis use.",[436,343,28],"Psychosis",[438,232,439,440],"alcohol","action based cognitive remediation","psychosis","2026-04-01",{"date":443,"type":37},"2026-04-07",{"date":445,"type":22},"2026-03-27",{"date":447,"type":22},"2028-03-31",{"name":449,"class":44},"Nova Scotia Health Authority",2,{"id":452,"slug":4,"hasResults":11,"nctId":453,"briefTitle":454,"officialTitle":454,"acronym":4,"eligibilityCriteria":455,"healthyVolunteers":191,"sex":17,"minAge":150,"maxAge":18,"enrollmentInfo":456,"targetDuration":4,"studyType":54,"phases":458,"briefSummary":459,"conditions":460,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":461,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":45},"100525677","NCT06124846","Determining the Effect of Six Weeks of Cannabis Abstinence on Fronto- Striatal fMRI Markers in Adolescents With Cannabis Use Disorder (ABSCAN)","Inclusion Criteria:\n\n* Male and female adolescents between the ages of 15 and 18 (inclusive).\n* Have a parent or legal guardian who is able and willing to provide written informed consent.\n* Competent and willing to provide written informed assent (participants \\\u003C18) or consent (participants=18).\n* Native English speaker.\n* Have a parent or legal guardian who is fluent in English.\n* Able to commit to 9 study visits in approximately 60 days (6 weeks).\n* Able to safely participate in the protocol and appropriate for outpatient level of care, in the opinion of the PI.\n* No active psychosis or current use of antipsychotic medications.\n* Participants taking psychotropic medications will be included if the medications have been stable for 6 weeks and are expected to remain stable for the duration of their study participation (i.e., through the third MRI).\n* For CB-Abst (n=24) and CB-Mon (n=20) groups: at least 5 days of use per week on average in the past two months and meet DSM-V cannabis use disorder (CUD; at least Mild) criteria. Cannabis use reported within seven days of baseline visit. Positive qualitative urine toxicology test at baseline for THC. No immediate plan to discontinue cannabis use.\n* For Con (n=20): no lifetime history of cannabis use. Negative qualitative urine toxicology test at baseline for THC. No immediate plans to begin cannabis use.\n* For optional components (A: daily remote assessments during and\u002For (B) after treatment period): access to a personal device (e.g., smartphone or computer) on which to complete daily remote assessments.\n\nExclusion Criteria:\n\n* Past twelve-month history of substance use disorders (except for Cannabis Use Disorder in CB-Abst and CB-Mon), assessed via semi-structured psychodiagnostics interview at baseline.\n* Contraindications for MRI (ascertained via participant and parent report), including but not limited to:\n\n  1. Metal implants such as surgical clips or pacemakers, or history of working with metal, unless the possibility of a metal fragment can be ruled out by recent orbital scans.\n  2. Prior head trauma with neurological sequelae.\n  3. Claustrophobia.\n  4. Weight incompatible with MRI safety.\n  5. Pregnancy.\n* Previous or current diagnosis of psychosis, cognitive disability, or bipolar disorder.\n* Active suicidality.\n* Taking a psychotropic medication that has not reached stability criterion (same medication type and dose for 6 weeks with no planned changes over the study period).\n* Any other medical or psychiatric condition deemed serious or contraindicated for any study procedures by Dr. Tervo-Clemmens.",{"count":457,"type":22},64,[56],"The goal of this study is to understand the changes in neural correlates of reward in adolescents with and without Cannabis Use Disorder (CUD). The study will collect functional magnetic resonance imaging (fMRI) data at 3 different timepoints with the primary goals of understanding striatal reward-based activation during a Monetary Incentive Delay Task and fronto-striatal fMRI resting-state functional connectivity. The study will also explore self-reported impulsivity. The long-term goal is to advance scientific understanding of neural changes associated with cannabis abstinence and inter-individual variability that cannot be otherwise measured in preexisting observational cohorts such as the Adolescent Brain Cognitive Development Study.\n\nThis parallel intervention study will collect fMRI data in adolescents ages 15-18 years old with and without CUD at three different timepoints over the course of their intervention. Utilizing a validated paradigm, adolescents with CUD will be randomized to 6-weeks of either incentivized, biochemically verified abstinence via contingency management or monitoring with no required abstinence. Age- and sex-matched adolescents with no lifetime history of cannabis use will also complete the protocol. Participants will complete 9 study visits (3 with fMRI scans) involving urinalysis to confirm cannabis self-report and measures of impulsivity. Participants may additionally and optionally (1) complete daily remote self-report assessments of cannabis use, impulsivity, and mood throughout the 6-week treatment period, and (2) continue participation for an additional 6-week monitoring period after the treatment period, during which they complete daily remote self-report assessments of cannabis use, impulsivity, and mood.",[28],{"date":443,"type":37},{"date":463,"type":37},"2024-04-01",{"date":465,"type":22},"2028-04-15",{"name":164,"class":44},{"id":468,"slug":4,"hasResults":11,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":4,"eligibilityCriteria":472,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":363,"enrollmentInfo":473,"targetDuration":4,"studyType":54,"phases":474,"briefSummary":475,"conditions":476,"keywords":477,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":45},"100505283","NCT05859347","Repetitive Transcranial Magnetic Stimulation for Cannabis Use Disorder","Development of a Novel, Scalable, Neurobiologically-Guided Transcranial Magnetic Stimulation Protocol for the Treatment of Cannabis Use Disorder","Inclusion Criteria:\n\n1. Must be deemed to have capacity to provide informed consent\n2. Age between 18 to 65\n3. Diagnosis of cannabis use disorder according to the DSM-5 and the Structured Clinical Interview for DSM-5 (SCID for DSM-541)\n4. Report cannabis as the primary drug of concern, a frequent pattern of use (≥5 days per week), and a goal of reduction or abstinence of cannabis use\n5. CUDIT-R score ≥12\n6. Marijuana Contemplation Ladder ≥7\n7. Cannabis positive urine drug screen, with Narcochek baseline THC-COOH level of \\>150 ng\u002Fml.\n8. On a stable regimen of their psychotropic medications for 14 days before enrolment.\n\nExclusion Criteria:\n\n1. Pregnant or intending to be pregnant during the study\n2. Diagnosis of bipolar disorder, schizophrenia spectrum disorder, or other active concurrent psychiatric disorder that is too unstable and may preclude safe participation in the trial as deemed by the PI.\n3. Substance use disorder other than cannabis or nicotine, that is of moderate severity or greater, or is the primary substance of concern based on the SCID for DSM-5\n4. Known active seizure disorder, significant head injury with an imaging verified lesion\n5. Unstable medical illness\n6. Presence of cardiac pacemaker, intracranial implant, or metal in the cranium\n7. Participants taking \\> 2 mg lorazepam (or a benzodiazepine at an equivalent dose) or taking any anticonvulsant medication during treatment.",{"count":365,"type":22},[56],"There has been a considerable rise in cannabis consumption in recent years, with estimates of 200 million individual users globally. Importantly, 3% of these individuals have cannabis use disorder (CUD), with this prevalence increasing to 33% amongst regular users, making it one of the most common substances use disorders (SUDs) worldwide. CUD is associated with substantial health, societal, and economic costs, and worsening of other psychiatric disorders. Despite this clinical burden, effective treatment options are limited. No pharmacological treatments have emerged as clearly efficacious, and psychotherapeutic interventions have shown tempered results.\n\nRepetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain-based approach in which alternating magnetic fields are applied to the scalp to induce electrical currents in cortical tissue. As it can modulate neural circuits implicated in neuropsychiatric disorders, it is a promising brain-based approach in the treatment of addictions. Evidence has indicated its efficacy in reducing drug craving and consumption across numerous SUDs, although research into cannabis has been largely unexplored. Recently, a novel circular rTMS coil, the MagVenture MMC-140, has been developed with the capacity to modulate both the bilateral prefrontal cortex (PFC) and insula, both of which are implicated in the neurocircuitry of craving and executive function. As such, it shows potential for CUD treatment.\n\nThis proof-of-concept clinical trial will evaluate the feasibility and tolerability of a 4-week course of rTMS to the PFC\u002Finsula using MMC-140 as a treatment for CUD. Feasibility of both high frequency (HF; excitatory) and low frequency (LF; inhibitory) stimulation parameters will be evaluated. In addition, pre\u002Fpost rTMS changes in cannabis use outcomes (e.g., consumption, craving, and withdrawal), executive function, and PFC\u002Finsula functional connectivity will be explored. By comprehensively investigating clinical, cognitive, and neuroimaging effects of rTMS, this study could pave the way for the first brain-based intervention in CUD that could be widely adopted into clinical settings using a novel, cost-effective and accessible rTMS device.",[28],[478,108,479,480,481,203],"Repetitive Transcranial Magnetic Stimulation","Substance Use Disorder","Prefrontal Cortex","Insula","2026-03-26",{"date":445,"type":37},{"date":485,"type":37},"2023-05-15",{"date":487,"type":22},"2027-06-15",{"name":489,"class":44},"Centre for Addiction and Mental Health",{"id":491,"slug":4,"hasResults":11,"nctId":492,"briefTitle":493,"officialTitle":493,"acronym":4,"eligibilityCriteria":494,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":495,"targetDuration":4,"studyType":54,"phases":497,"briefSummary":498,"conditions":499,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":45},"100505002","NCT05855668","Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment","Inclusion Criteria:\n\n1. Patient has been referred to or intends to participate in either the AUD or CUD Integrated Care Pathway (and is therefore willing to participate in group psychotherapy).\n2. Able to communicate and provide informed consent in English.\n3. 18 years of age or older.\n4. Willing and able to safely abstain from substances (other than nicotine or tobacco products), including alcohol and cannabis, for 12 hours prior to the eligibility and task-based assessments.\n5. Meets DSM-5 diagnostic criteria for AUD (AUD group) or CUD (CUD group)\n6. Meets criteria for risky drinking, defined as \\> 10 drinks per week for females and \\> 15 drinks per week for males on average over the past 30 days (AUD group) or daily or near-daily cannabis use over the past 30 days, defined as ≥ 4 days of cannabis use per week on average (CUD group)\n\nExclusion Criteria:\n\n1. Active suicidal ideation at time of assessment.\n2. Suicide attempt within the past month.\n3. Unstable psychiatric or medical status (e.g., acute psychosis or mania) or unstable use of another substance that may interfere with participation in groups (e.g. active fentanyl use).\n4. Enrollment in another study that conflicts with the procedures or scientific integrity of this study.\n5. Individuals planning to be out of the province for a substantial amount of time during the treatment period will not be permitted to enroll.",{"count":496,"type":22},400,[56],"This 2-arm study will recruit participants with 1) alcohol use disorder and 2) cannabis use disorder for a 12-week cognitive behavioral therapy, following a thorough baseline assessments on executive function, incentive salience, and negative emotionality.",[343,28],"2026-03-19",{"date":502,"type":37},"2026-03-20",{"date":504,"type":37},"2022-11-10",{"date":506,"type":22},"2027-12",{"name":489,"class":44},{"id":509,"slug":4,"hasResults":11,"nctId":510,"briefTitle":511,"officialTitle":512,"acronym":4,"eligibilityCriteria":513,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":514,"targetDuration":4,"studyType":54,"phases":516,"briefSummary":517,"conditions":518,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":45},"100609737","NCT07218471","Cannabis Reduction and Functional Outcomes","Prospective Changes in Patient-reported and Objective Functioning Following Reduction of Cannabis Use","Inclusion Criteria:\n\n* Age 18+\n* Urinary cannabinoid level ≥ 50 ng\u002FmL\n* DSM-5 diagnosis of CUD (mild, moderate, or severe)\n* Willingness to attempt cannabis reduction\n* Completion of Intake Visit\n\nExclusion Criteria:\n\n* Serious medical\u002Fpsychiatric conditions\n* Pregnancy or breastfeeding\n* Use of cannabis in past 30 days was for medical purposes only\n* Discontinuation or reduction of cannabis use may exacerbate a pre-existing condition\n* Cognitive or understanding difficulties, as evidenced by inability to pass informed consent quiz",{"count":515,"type":22},176,[56],"This study evaluates the effects of cannabis use reduction among adults diagnosed with cannabis use disorder (CUD). Participants will undergo an 8-week intervention combining motivational interviewing, computerized cognitive behavioral therapy (CBT4CBT), and financial incentives for reduction in urinary cannabinoids. The study aims to assess improvements in cannabis-related problems, sleep, cognitive performance, CUD severity, and quality of life.",[28],"2026-03-16",{"date":500,"type":37},{"date":522,"type":37},"2026-03-13",{"date":524,"type":22},"2030-01-30",{"name":271,"class":44},{"id":527,"slug":4,"hasResults":11,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":532,"targetDuration":4,"studyType":54,"phases":534,"briefSummary":536,"conditions":537,"keywords":538,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":45},"100566838","NCT06660381","Psilocybin-assisted Treatment for Cannabis Use Disorder","Pilot Study of Psilocybin-assisted Treatment for Cannabis Use Disorder","Inclusion Criteria:\n\n* ≥ 18 years of age.\n* Capable of providing written informed consent for participation into the study.\n* Willingness to allow the study team to review past medical records.\n* Currently meets criteria for The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnosis of Cannabis Use Disorder.\n* Be medically stable as determined by screening for medical problems via a personal interview, a medical questionnaire, a physical examination, an electrocardiogram (ECG), and routine medical blood and urinalysis laboratory tests.\n* Concurrent pharmacotherapy with selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and\u002For bupropion is allowed if the type and frequency of the therapy has been stable for at least two months prior to screening. Allowable bupropion doses for participants will be ≤300mg\u002Fday.\n\nExclusion Criteria:\n\n* Meeting DSM-5 criteria for another moderate or severe substance use disorder (excluding tobacco) within the past 5 years.\n* Currently taking antipsychotics, monoamine oxidase (MAO) inhibitors, or antidepressant medications other than SSRIs, SNRIs, or bupropion. Allowable bupropion doses for participants will be ≤300mg\u002Fday.\n* Currently taking lithium or other primary centrally-acting serotonergic medications, whether over-the-counter or prescription (e.g., efavirenz, 5-hydroxytryptophan, St. John's wort).\n* Cardiovascular conditions: angina, a clinically significant ECG abnormality (e.g. atrial fibrillation or corrected QT interval (QTc) \\> 450 msec), transient ischemic attack (TIA) in the last 6 months, stroke, artificial heart valves, or uncontrolled hypertension with resting blood pressure systolic \\>139 or diastolic \\>89, or heart rate \\>90 bpm.\n* Body weight at screening \\\u003C50kg.\n* Renal disease (creatinine clearance \\\u003C 60 ml\u002Fmin using the Cockraft and Gault equation).\n* Abnormal screening labs values for hemoglobin, white blood count, creatinine, potassium, and bilirubin outside of the normal lab reference rage.\n* Transaminases greater than x2 the upper limit of normal lab reference range.\n* Current or past history of meeting DSM-5 criteria for Schizophrenia, Psychotic Disorder (unless substance-induced or due to a medical condition), or Bipolar I or II Disorder.\n* Family (i.e., 1st degree relative) history of Schizophrenia, Psychotic Disorder (unless substance-induced or due to a medical condition), or Bipolar I Disorder.\n* Epilepsy with history of seizures.\n* Insulin-dependent diabetes; if taking oral hypoglycemic agent, then no history of hypoglycemia.\n* Current dementia or related disorders including but not limited to, Alzheimer's Disease, vascular dementia, Lewy body dementia, and frontotemporal disorders.\n* Current or past major immunosuppressive illness or medications.\n* Currently pregnant or nursing.\n* Currently of childbearing potential and not using effective methods of contraception (i.e., intrauterine systems\u002Fdevices, hormonal methods including implant, shot, patch, ring, or oral contraceptive, condom, diaphragm, sterilization, abstinence, and fertility-awareness methods).\n* Not fluent in English.\n* High risk for suicidal ideation or behavior (i.e., individuals who report suicidal ideation with intent or behavior on the Columbia Suicide Severity Rating Scale (C-SSRS) at screening, or individuals with a suicide attempt within the past 3 years).",{"count":533,"type":22},12,[535],"PHASE1","This pilot study will evaluate the therapeutic potential of psilocybin in people with Cannabis Use Disorder (CUD). This study will examine the impact of psilocybin treatment on cannabis use and related variables in 12 people with CUD. This is an open-label proof-of-concept trial in which participants will complete a 12-week course of study treatment including two psilocybin sessions with psychological support, and follow-up assessments 3 and 6 months after the first psilocybin session.",[28],[232,539],"cannabis dependence",{"date":541,"type":37},"2026-03-18",{"date":543,"type":37},"2024-11-08",{"date":545,"type":22},"2026-12",{"name":547,"class":44},"Johns Hopkins University",{"id":549,"slug":4,"hasResults":11,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":219,"enrollmentInfo":554,"targetDuration":4,"studyType":54,"phases":555,"briefSummary":556,"conditions":557,"keywords":558,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":567,"locationsCount":4},"100628969","NCT07468552","Trial of Tirzepatide for the Treatment of Cannabis Use Disorder","Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Tirzepatide for Treatment of Cannabis Use Disorder (CUD)","Inclusion Criteria:\n\n* Between 18 and 70 years of age\n* Meets DSM-5 criteria for moderate or severe CUD\n* Interested in treatment for cannabis use disorder\n* Able to understand the study procedures and written informed consent in English\n* Willing to comply with all study procedures and medication instructions\n* If female, is not pregnant, and agrees to use acceptable birth control methods\n\nExclusion Criteria:\n\n* Body Mass Index (BMI) ≤ 23 kg\u002Fm²\n* Presence of a medical or psychiatric disorder that contraindicates participation in the study\n* Substance use disorder other than tobacco or mild alcohol-use disorder\n* Known allergy or hypersensitivity to Tirzepatide, any GLP-1 or GIP receptor agonist, or any of the excipients in the product\n* Current or recent (past 30 days) use of GLP-1 receptor agonists or other weight-loss drug\n* Current or recent (past 6 months) enrollment in substance use disorder treatment\n* Current or planned pregnancy and breastfeeding\n* Living or medical situation that would interfere with adherence to the study protocol",{"count":221,"type":22},[129],"The purpose of this randomized, double-blind, placebo-controlled, multi-site clinical trial is to evaluate the safety and efficacy of tirzepatide in a sample of 100 patients diagnosed with moderate or severe CUD by DSM-5 criteria.",[28],[26,226,559],"Marijuana Addiction","2026-03-09",{"date":562,"type":37},"2026-03-12",{"date":564,"type":22},"2026-11-15",{"date":566,"type":22},"2028-11-15",{"name":568,"class":569},"National Institute on Drug Abuse (NIDA)","NIH",{"id":571,"slug":4,"hasResults":11,"nctId":572,"briefTitle":573,"officialTitle":573,"acronym":4,"eligibilityCriteria":574,"healthyVolunteers":191,"sex":17,"minAge":18,"maxAge":575,"enrollmentInfo":576,"targetDuration":4,"studyType":54,"phases":578,"briefSummary":580,"conditions":581,"keywords":583,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":589,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":594,"locationsCount":45},"100475583","NCT05472818","SV2A Density Cannabis Use Disorder","CUD Participants Inclusion Criteria:\n\n1. Able to provide informed consent\n2. Male and female 18-75 years old\n3. Daily cannabis use\n4. Positive urine screen for cannabinoids and negative for all other drugs on\n5. Diagnosis of DSM-5 cannabis use disorder (≥ moderate, i.e., ≥ 4 \\[of 11\\] symptoms).\n6. Must express a willingness at screening to set a date to attempt to quit using cannabis.\n7. Physically healthy i.e., no clinically unstable medical conditions.\n8. For women of childbearing potential (WOCBP) and men, willingness to practice birth control and to inform study staff immediately if either they (for women) or their partner (for men) becomes pregnant.\n9. Additional criteria not disclosed here in order to minimize the risk of ineligible subjects enrolling in the study.\n\nCUD Participants Exclusion Criteria:\n\n1. Laboratory tests with clinically significant abnormalities or positive urine toxicology screen with exception of cannabinoids.\n2. Women with a positive pregnancy test or women who are lactating.\n3. Have implanted or embedded metal objects or fragments in the head or body that would present a risk during the MRI scanning procedure, or have worked with ferrous metals either as a vocation or hobby (for example, as a sheet metal worker, welder, or machinist) in such a way that might have led to unknown, indwelling metal fragments that could cause injury if they moved in response to placement in the magnetic field\n4. Have had exposure to ionizing radiation that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits.\n5. History of a bleeding disorder or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto) Subjects who have donated blood within 8 weeks of the present study\n6. Medications that could alter synaptic density and, therefore, confound the interpretation of study data.\n7. Additional criteria not disclosed here in order to minimize the risk of ineligible subjects enrolling in the study.\n\nHealthy Controls Inclusion Criteria:\n\n1. Willing and able to give voluntary written informed consent\n2. Male and Female subjects, age 18 to 75 years, inclusive\n3. BMI within 19 to 35 kg\u002Fm2, inclusive\n4. Must be in good health as determined by medical history, physical examination, ECG, serum\u002Furine biochemistry, hematology, and serology tests.\n5. Negative urine drug screen\n6. If female, not pregnant or breastfeeding\n7. If female of childbearing potential, must agree to use an acceptable method of birth control, as determined by the principal investigator, for the duration of the study and up to one month after completion of PET scans.\n8. Able to read and write, able to communicate effectively with the investigator, and comply with all study requirements, restrictions, and directions of the clinic staff.\n9. Have arterial access sufficient to allow blood sampling as per the protocol.\n\nHealthy Controls Exclusion Criteria:\n\n1. History or presence of clinically significant and unstable respiratory, GI, renal, hepatic, pancreatic, hematological, neurological (including history of seizure), cardiovascular, psychiatric (including known addictive disorders), musculoskeletal, genitourinary, immunological, or dermatological disorders, including all cancers.\n2. Abnormal clinically significant laboratory or physical findings during screening\n3. History of a bleeding disorder or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto)\n4. A condition that, in the opinion of the investigator, would prevent compliance with the study protocol.\n5. Medications that could alter synaptic density and, therefore, confound the interpretation of study data.\n6. MRI incompatible implants and other contraindications for MRI, such as pace-maker, artificial joints, non-removable body piercings, metal fragments in head and\u002For body, or history working with ferrous metals either as a vocation or hobby in such a way that might have led to unknown, indwelling metal fragments that could cause injury during MRI etc.\n7. Subjects who suffer from claustrophobia.\n8. Participation in other research studies involving ionizing radiation within one year of the PET scans that would cause the subject to exceed the yearly dose limits for healthy volunteers\n9. Additional criteria not disclosed here in order to minimize the risk of ineligible subjects enrolling in the study.","75 Years",{"count":577,"type":22},51,[579],"EARLY_PHASE1","The main purpose of this study is to determine whether hippocampal synaptic vesicle density estimated by hippocampal \\[11C\\]APP-311\u002F\\[11C\\]UCB-J binding in individuals diagnosed with cannabis use disorder (CUDs) improves with at least 4 weeks of confirmed abstinence from cannabis, in comparison to healthy controls (HCs). Furthermore, any change in synaptic vesicle density will be placed in functional context by measuring verbal memory, which is sensitive to hippocampal function, before and after at least 4 weeks of confirmed abstinence. Finally, the relationship between hippocampal \\[11C\\]UCB-J binding in CUDs with measures of cannabis exposure (e.g., age of initiation, cumulative lifetime dose) will be explored.",[28,582],"Healthy",[584,585,586,587,588],"Cannabis Use Disorder (CUD)","Healthy subjects","synaptic vesicle density","[11C]APP311","UCB-J",{"date":562,"type":37},{"date":591,"type":37},"2022-04-12",{"date":593,"type":22},"2032-05",{"name":329,"class":44},{"id":596,"slug":4,"hasResults":11,"nctId":597,"briefTitle":598,"officialTitle":599,"acronym":600,"eligibilityCriteria":601,"healthyVolunteers":11,"sex":17,"minAge":77,"maxAge":125,"enrollmentInfo":602,"targetDuration":4,"studyType":54,"phases":604,"briefSummary":605,"conditions":606,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":608,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":614,"locationsCount":450},"100546479","NCT06395467","Integrated Treatment for Enhancing Growth in Recovery During Adolescence","Integrated Treatment for Enhancing Growth in Recovery During Adolescence (InTEGRA)","InTEGRA","Inclusion criteria:\n\n1. 14-21 years old\n2. SUD based on criteria from the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)\n3. able to read and comprehend English at a 5th-grade level\n4. residence in Eastern time zone states (Connecticut, Delaware, Florida, Georgia, Indiana, Kentucky, Maine, Maryland, Massachusetts, Michigan, New Hampshire, New Jersey, New York, North Carolina, Ohio, Pennsylvania, Rhode Island, South Carolina, Tennessee, Vermont, Virginia, and West Virginia\n5. any AOD use in the past 90 days (or in the 90 days prior to being in a controlled environment)\n6. meet patient placement criteria for level I (outpatient) treatment\n7. participant and a family member\u002Fguardian responsible for providing collateral information (for those \\\u003C18 years) agree to sign Institutional Review Board (IRB)-approved consent\n8. participant and family member responsible for providing collateral information who could be contacted in case the subject became lost to follow-up.\n\nExclusion criteria:\n\n1. suicidal ideation with a plan, suicidal behavior, a plan to hurt oneself or others, or a history of self-injurious behavior occurring in past 30 days\n2. lifetime diagnosis of schizophrenia\n3. current health condition (i.e., medical, psychiatric) that compromises participant's ability to attend outpatient treatment\n4. demonstrate inability or unwillingness to identify a \"locator\" who could be contacted in case participant becomes lost to follow-up; or\n5. youth attending another SUD treatment program or receiving psychotherapy that could conflict with study treatments.",{"count":603,"type":22},294,[56],"This is a Phase II parallel group randomized controlled trial with 294 adolescents (age: 14-21 years) with alcohol and other drug \\[AOD\\] use disorder (hereafter substance use disorder), that compares two different active psychosocial interventions designed to address adolescent substance use disorder. Participants are recruited from our clinical settings and the community at two sites: one in the metro Boston, Massachusetts (MA) area and the other in the metro Farmington, Connecticut (CT), area.\n\nStudy aims and hypotheses are as follows:\n\n1. To extend the evidence for the initial efficacy of Integrated Treatment for Enhancing Growth in Recovery During Adolescence (InTEGRA), which integrates 12-Step Facilitation (TSF) with Motivational Enhancement Therapy\u002FCognitive Behavioral Therapy (MET\u002FCBT) relative to gold standard MET\u002FCBT alone (N = 294). It is hypothesized that youth assigned to InTEGRA will have greater 12-step participation during and following treatment, higher abstinence rates, and fewer substance-related negative consequences.\n2. Investigate the personal recovery capital (PRC) and social recovery capital (SRC) mechanisms of behavior change through which InTEGRA may confer benefits dynamically over time (e.g., PRC: motivation, self-efficacy, coping; SRC: 12-step involvement; social network changes).\n3. Investigate moderators of InTEGRA's effects on outcomes across one-year follow-up (e.g., effect of age, network support for AOD use; psychiatric severity; age composition of 12-step meetings on substance use and substance-related consequences). It is hypothesized that higher network support for AOD use, abstinence motivation, and greater AOD severity, will have a better response to InTEGRA.\n4. Explore barriers and facilitators to InTEGRA adoption and implementation across providers and system administrators within the context of a type I hybrid effectiveness-implementation research design.",[343,28],"2026-03-04",{"date":609,"type":37},"2026-03-06",{"date":611,"type":37},"2024-11-26",{"date":613,"type":22},"2028-05-31",{"name":184,"class":44},""]